Successful CAR-T Cell Treatment of JAK1/2 Inhibitor Treatment Induced DLBCL (EHA-EBMT-CART 2023)
Ruxolitinib was discontinued and the patient received two cycles of RR-EPOCH, four cycles of R-COMP and lenalidomide. While this treatment resulted in complete metabolic response, the patient was deemed eligible for CAR-T cell treatment by the lymphoma-board, because of the high-risk features of this lymphoma (immunosuppression associated, high IPI score and double expressor score of 2).After bridging with polatuzumab-vedotin-bendamustin, the patient received axicabtagene ciloleucel on 22.11.2021... Therapy of JAK1/2 inhibitor associated aggressive B-Cell lymphoma is feasible and results in durable remissions with acceptable toxicity.Figure 1DateJAK2 V617F Allelic burden(Sample site: peripheral blood)17.07.20192,108%27.08.20192,038%29.10.20191,37816.10.20200,889%04.03.20210,814%23.08.20210,275%15.09.20210,528%12.01.20221,101%23.02.20220,645%Table 1